Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen

Omeros (NASDAQ:OMER) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other research analysts have also recently weighed in on OMER. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. WBB Securities restated a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a research note on Wednesday, October 15th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Thursday. HC Wainwright lifted their target price on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Trading Down 7.1%

OMER opened at $12.49 on Friday. The stock’s 50-day moving average price is $10.58 and its 200 day moving average price is $6.64. Omeros has a 12-month low of $2.95 and a 12-month high of $17.65. The firm has a market cap of $885.54 million, a price-to-earnings ratio of -6.18 and a beta of 2.38.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.39. On average, research analysts forecast that Omeros will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Several hedge funds and other institutional investors have recently made changes to their positions in the business. B. Riley Wealth Advisors Inc. acquired a new position in Omeros in the second quarter valued at approximately $32,000. Harbour Investments Inc. boosted its holdings in shares of Omeros by 46.1% in the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares in the last quarter. Sei Investments Co. purchased a new position in shares of Omeros in the 2nd quarter valued at $40,000. Finally, Russell Investments Group Ltd. raised its stake in Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros News Roundup

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $40 and kept a Buy rating, highlighting large upside vs. the current share level — this upgrade is a clear bullish catalyst. HC Wainwright PT raise
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating with a $36 price target, providing additional analyst support for upside. D. Boral Capital reaffirmation
• Positive Sentiment: Omeros announced pricing for YARTEMLEA at $36,000 per single‑dose vial — a premium price that boosts near‑term revenue potential for its recently approved transplant complication therapy. Reuters: pricing
• Positive Sentiment: Company comments on FDA approval and commercialization plans for YARTEMLEA underline management’s readiness to commercialize and support uptake, which can validate the higher price target narratives. Seeking Alpha transcript
• Neutral Sentiment: HC Wainwright published detailed near‑term EPS forecasts (Q1–Q4 2026 showing losses) while projecting a large turnaround by FY2030 (EPS $6.69); this signals long‑term optimism but acknowledges multi‑year losses.
• Neutral Sentiment: Needham reiterated a Hold rating, reflecting balanced risk/reward as YARTEMLEA ramps. Needham Hold note
• Neutral Sentiment: There was a reported after‑hours bounce recently, indicating volatile trading around the approval/pricing news rather than steady directional conviction. MSN after‑hours
• Negative Sentiment: Near‑term financials remain loss‑making (consensus and HC Wainwright 2026 EPS estimates are negative), which can pressure the stock until commercial execution and revenue ramp are proven.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.